# Lokelma for RAAS Maximisation in CKD & Heart Failure.

Study · id `cardio:ct-nct05004363` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05004363](<https://clinicaltrials.gov/study/NCT05004363>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05004363

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 112 participants.

## Technical summary

Registry record NCT05004363. Randomized; quadruple masking; primary purpose treatment. Start 2022-01-19 (actual); primary completion 2024-07-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 112 participants (enrolled count; ClinicalTrials.gov record NCT05004363, source copy `cardio:ctgov-nct05004363-2026-04-27`, retrieved 2026-11-18)
- Started: 2022-01-19 (actual) (ClinicalTrials.gov record NCT05004363, source copy `cardio:ctgov-nct05004363-2026-04-27`, retrieved 2026-11-18)
- Primary completion: 2024-07-01 (actual) (ClinicalTrials.gov record NCT05004363, source copy `cardio:ctgov-nct05004363-2026-04-27`, retrieved 2026-11-18)
- Completion: 2024-07-01 (actual) (ClinicalTrials.gov record NCT05004363, source copy `cardio:ctgov-nct05004363-2026-04-27`, retrieved 2026-11-18)
- Countries: United Kingdom (ClinicalTrials.gov record NCT05004363, source copy `cardio:ctgov-nct05004363-2026-04-27`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05004363-2026-04-27`, retrieved 2026-11-18)

## The registry's words

- Brief title: Lokelma for RAAS Maximisation in CKD & Heart Failure.
- Acronym: LIFT
- Condition: Chronic Kidney Diseases
- Condition: Heart Failure With Reduced Ejection Fraction
- Condition: Hyperkalemia
- Condition: ACE Inhibitor Induced Hyperkalaemia
- Condition: Mineralocorticoid Resistant Hyperkalemia
- Intervention (Drug): Lokelma Oral Product
- Lead sponsor: St George's, University of London
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Rapid Renin Angiotensin Aldosterone System inhibitor optimisation in patients with chronic kidney disease and heart failure with reduced ejection fraction using potassium binder: a randomised, double-blinded, placebo-controlled trial (`cardio:pubmed-43015282`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 6fbf3f9ccd7a573d89a556d00e1098d9ed61f50dbf08702f9557902bf509d4ce
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
